journal
MENU ▼
Read by QxMD icon Read
search

Journal of Managed Care & Specialty Pharmacy

journal
https://www.readbyqxmd.com/read/29927346/the-effect-of-medical-technology-innovations-on-patient-outcomes-1990-2015-results-of-a-physician-survey
#1
David E Wamble, Michael Ciarametaro, Robert Dubois
BACKGROUND: Developments in diagnostics, medical devices, procedures, and prescription drugs have increased life expectancy and quality of life after diagnosis for many diseases. Previous research has shown that, overall, increased investment in medical technology has led to increased health outcomes. In addition, the value of investment in specific innovations, particularly in new pharmaceuticals or biopharmaceuticals, has frequently been shown through an evaluation of the associated health outcomes and costs...
June 21, 2018: Journal of Managed Care & Specialty Pharmacy
https://www.readbyqxmd.com/read/29897007/an-economic-evaluation-of-tofacitinib-treatment-in-rheumatoid-arthritis-after-methotrexate-or-after-1-or-2-tnf-inhibitors-from-a-u-s-payer-perspective
#2
Lindsay Claxton, Matthew Taylor, Arif Soonasra, Jeffrey A Bourret, Robert A Gerber
BACKGROUND: Treatment cycling with biologic disease-modifying anti-rheumatic drugs, such as tumor necrosis factor inhibitors (TNFi), is common among patients with rheumatoid arthritis (RA) and can result in reduced clinical efficacy and increased economic burden. Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA. OBJECTIVE: To evaluate and compare the economic effect of tofacitinib 5 mg twice daily (BID) treatment directly after methotrexate (MTX) in the MTX-inadequate responder population, or after MTX and 1 TNFi (adalimumab [ADA] or etanercept [ETN]) or 2 TNFi (ADA and ETN) in TNF-inadequate responder patients with RA, from a U...
June 13, 2018: Journal of Managed Care & Specialty Pharmacy
https://www.readbyqxmd.com/read/29877140/risk-factors-health-care-resource-utilization-and-costs-associated-with-nonadherence-to-antiretrovirals-in-medicaid-insured-patients-with-hiv
#3
Keith Dunn, Marie-Hélène Lafeuille, Xiaolong Jiao, Hela Romdhani, Bruno Emond, Kimberly Woodruff, Jacqueline Pesa, Neeta Tandon, Patrick Lefebvre
BACKGROUND: Adherence to antiretrovirals (ARVs) is critical to achieving durable virologic suppression. OBJECTIVE: To investigate risk factors of poor adherence and the effect of suboptimal adherence on health care resource utilization (HCRU) and costs in Medicaid patients. METHODS: A retrospective longitudinal study was conducted using Medicaid data. Adults (aged ≥ 18 years) with human immunodeficiency virus (HIV)-1 initiating selected ARVs (index date) were identified...
June 7, 2018: Journal of Managed Care & Specialty Pharmacy
https://www.readbyqxmd.com/read/29848186/the-effect-of-an-educational-intervention-on-adherence-to-intraocular-pressure-lowering-medications-in-a-large-cohort-of-older-adults-with-glaucoma
#4
Richard Fiscella, Eleanor Caplan, Pravin Kamble, Suvapun Bunniran, Claudia Uribe, Hitesh Chandwani
BACKGROUND: Glaucoma is a progressive, irreversible disease that can lead to vision loss and lower quality of life if treatment is not optimized. Effective glaucoma therapies are available to lower intraocular pressure (IOP) and minimize or delay disease progression. Nonetheless, adherence to treatment remains suboptimal for many patients. OBJECTIVE: To identify potentially nonadherent patients and evaluate the effect of patient- and physician-centric educational interventions on adherence by using a validated predictive model of nonadherence to glaucoma medication...
May 31, 2018: Journal of Managed Care & Specialty Pharmacy
https://www.readbyqxmd.com/read/29791243/amcp-partnership-forum-managing-care-in-the-wave-of-precision-medicine
#5
(no author information available yet)
Precision medicine, the customization of health care to an individual's genetic profile while accounting for biomarkers and lifestyle, has increasingly been adopted by health care stakeholders to guide the development of treatment options, improve treatment decision making, provide more patient-centered care, and better inform coverage and reimbursement decisions. Despite these benefits, key challenges prevent its broader use and adoption. On December 7-8, 2017, the Academy of Managed Care Pharmacy convened a group of stakeholders to discuss these challenges and provide recommendations to facilitate broader adoption and use of precision medicine across health care settings...
May 23, 2018: Journal of Managed Care & Specialty Pharmacy
https://www.readbyqxmd.com/read/29694270/higher-incidence-rates-of-comorbidities-in-patients-with-psoriatic-arthritis-compared-with-the-general-population-using-u-s-administrative-claims-data
#6
Jeffrey Kaine, Xue Song, Gilwan Kim, Peter Hur, Jacqueline B Palmer
BACKGROUND: Psoriatic arthritis (PsA) is associated with multiple comorbid conditions, including cardiovascular (CV) comorbidities that impose a considerable burden on patients. Effective management of PsA requires an understanding of comorbidity profiles. OBJECTIVE: To compare the frequency and incidence rates of comorbidities and hospitalizations among newly diagnosed PsA patients and a matched general population without PsA, using large national claims databases in the United States...
April 25, 2018: Journal of Managed Care & Specialty Pharmacy
https://www.readbyqxmd.com/read/29687743/clinical-outcomes-of-treatment-with-filgrastim-versus-a-filgrastim-biosimilar-and-febrile-neutropenia-associated-costs-among-patients-with-nonmyeloid-cancer-undergoing-chemotherapy
#7
Lee S Schwartzberg, Lincy S Lal, Sanjeev Balu, Kim Campbell, Lee Brekke, Andrew DeLeon, Caitlin Elliott, Stephanie Korrer
BACKGROUND: Granulocyte colony-stimulating factors such as filgrastim are used to decrease the incidence of febrile neutropenia (FN) among patients with nonmyeloid cancers undergoing chemotherapy treatment. Although the biosimilar filgrastim-sndz has been approved in the United States since 2015, limited real-world comparisons of filgrastim-sndz versus reference filgrastim (filgrastim-ref) have been conducted. OBJECTIVE: To compare FN incidence and assess overall FN-related health care resource utilization and medical costs among U...
April 24, 2018: Journal of Managed Care & Specialty Pharmacy
https://www.readbyqxmd.com/read/29952714/serious-adverse-drug-events-reported-to-the-fda-analysis-of-the-fda-adverse-event-reporting-system-2006-2014-database
#8
Kalyani B Sonawane, Ning Cheng, Richard A Hansen
BACKGROUND: Data on adverse drug events (ADEs) observed at the population level provide important evidence regarding the safety of a pharmaceutical product in real-world settings. Recent patterns in serious and fatal ADE reporting have not been documented. OBJECTIVE: To assess recent patterns in serious and fatal ADE reports in the United States. METHODS: We conducted a retrospective analysis of the publicly available 2006-2014 FDA Adverse Event Reporting System database...
July 2018: Journal of Managed Care & Specialty Pharmacy
https://www.readbyqxmd.com/read/29952713/amcp-partnership-forum-managing-care-in-the-wave-of-precision-medicine
#9
(no author information available yet)
Precision medicine, the customization of health care to an individual's genetic profile while accounting for biomarkers and lifestyle, has increasingly been adopted by health care stakeholders to guide the development of treatment options, improve treatment decision making, provide more patient-centered care, and better inform coverage and reimbursement decisions. Despite these benefits, key challenges prevent its broader use and adoption. On December 7-8, 2017, the Academy of Managed Care Pharmacy convened a group of stakeholders to discuss these challenges and provide recommendations to facilitate broader adoption and use of precision medicine across health care settings...
July 2018: Journal of Managed Care & Specialty Pharmacy
https://www.readbyqxmd.com/read/29952712/real-world-characteristics-and-treatment-patterns-in-patients-with-urticaria-initiating-omalizumab-in-the-united-states
#10
Xuehua Ke, Abhishek Kavati, Debra Wertz, Qing Huang, Liya Wang, Vincent J Willey, Judith J Stephenson, Benjamin Ortiz, Brandee Paknis, Jonathan A Bernstein, Lisa A Beck
BACKGROUND: Omalizumab is indicated for the management of chronic idiopathic urticaria (CIU) in patients aged 12 years or older with persistent hives that are not adequately controlled by H1 antihistamines. While its safety and efficacy in CIU patients have been evaluated in multiple clinical trials, real-world use of omalizaumab in CIU has not been well characterized. OBJECTIVE: To assess demographics, clinical characteristics, and treatment patterns of CIU patients who initiated omalizumab to better understand the usage of this agent in CIU management in the real world...
July 2018: Journal of Managed Care & Specialty Pharmacy
https://www.readbyqxmd.com/read/29952711/sustained-virologic-response-and-costs-associated-with-direct-acting-antivirals-for-chronic-hepatitis-c-infection-in-oklahoma-medicaid
#11
Timothy T Pham, Shellie L Keast, Kevin C Farmer, David M Thompson, R Chris Rathbun, Nancy J Nesser, Bethany P Holderread, Grant H Skrepnek
BACKGROUND: Outcomes involving newer direct-acting antiviral (DAA) hepatitis C virus (HCV) regimens have not been studied extensively among the Medicaid population. OBJECTIVE: To assess clinical (treatment failure) and economic outcomes for chronic HCV-infected Oklahoma Medicaid members following treatment with DAAs and to measure associations with patient, treatment, and clinical characteristics. METHODS: This cross-sectional study used Oklahoma Medicaid pharmacy and medical claims data for adult members who used a newer DAA agent and had reported a successful or failed sustained virological response rate 12 weeks after therapy completion (SVR12) from January 1, 2014, to June 30, 2016...
July 2018: Journal of Managed Care & Specialty Pharmacy
https://www.readbyqxmd.com/read/29952710/evaluating-the-effect-of-treatment-persistence-on-the-economic-burden-of-moderate-to-severe-psoriasis-and-or-psoriatic-arthritis-patients-in-the-u-s-department-of-defense-population
#12
Seina Lee, Lin Xie, Yuexi Wang, Neel Vaidya, Onur Baser
BACKGROUND: Psoriasis is a chronic, hyper-proliferative dermatological condition associated with joint symptoms known as psoriatic arthritis (PsA). In a 2013 review, the total economic burden of PsA was estimated at $51.7-$63.2 billion. The economic burden of moderate to severe psoriasis patients has reduced significantly with the advent of biologics, but there remains a dearth of real-world evidence of the impact of treatment persistence on the economic burden of moderate to severe psoriasis and/or PsA patients...
July 2018: Journal of Managed Care & Specialty Pharmacy
https://www.readbyqxmd.com/read/29952709/hemophilia-burden-of-disease-a-systematic-review-of-the-cost-utility-literature-for-hemophilia
#13
Teja Thorat, Peter J Neumann, James D Chambers
BACKGROUND: Prophylaxis with clotting factor replacement products is recommended by the Medical and Scientific Advisory Council of the National Hemophilia Foundation as the optimal therapy for the prevention of bleeding episodes in individuals with severe hemophilia A or B (< 1 IU per dL endogenous factor VIII or factor IX activity, respectively). Prophylaxis is associated with an improved health-related quality of life and has been shown to be cost-effective compared with on-demand therapy...
July 2018: Journal of Managed Care & Specialty Pharmacy
https://www.readbyqxmd.com/read/29952708/effectiveness-of-ledipasvir-sofosbuvir-and-predictors-of-treatment-failure-in-members-with-hepatitis-c-genotype-1-infection-a-retrospective-cohort-study-in-a-medicaid-population
#14
George Kouris, Tasmina Hydery, Bonnie C Greenwood, Pavel Lavitas, Mylissa Price, Karen Clements, Caroline J Alper, Kimberly Lenz, Paul L Jeffrey
BACKGROUND: The primary goal of therapy for patients with chronic hepatitis C virus (HCV) infection is eradication of HCV ribonucleic acid, which is predicted by achievement of sustained virologic response at 12 weeks (SVR12). Ledipasvir/sofosbuvir was approved by the FDA in 2014 and 2015 as a once-daily regimen for the treatment of HCV genotype 1 and HCV genotypes 4, 5, and 6, respectively. Although its efficacy has been demonstrated in randomized controlled trials, there is an unmet need for real-world effectiveness data and studies that assess the association of rates of SVR12 with specific clinical and demographic factors in the Medicaid population...
July 2018: Journal of Managed Care & Specialty Pharmacy
https://www.readbyqxmd.com/read/29952707/intravitreal-aflibercept-versus-ranibizumab-for-wet-age-related-macular-degeneration-a-cost-effectiveness-analysis
#15
Luis Hernandez, Tereza Lanitis, Clifford Cele, Hector Toro-Diaz, Andrea Gibson, Andreas Kuznik
BACKGROUND: Age-related macular degeneration (AMD) is the leading cause of vision loss in the United States. The most severe vision loss occurs in patients with neovascular AMD, known as wet AMD (wAMD). The most commonly used antivascular endothelial growth factor (VEGF) therapies approved by the FDA to treat patients with wAMD are ranibizumab, 0.5 mg administered by intravitreal injection once a month (approximately every 28 days), and intravitreal aflibercept injection (IAI), 2 mg every 4 weeks (monthly) for the first 12 weeks (3 months), followed by IAI 2 mg once every 8 weeks (2 months)...
July 2018: Journal of Managed Care & Specialty Pharmacy
https://www.readbyqxmd.com/read/29952706/the-potential-effect-of-the-21st-century-cures-act-on-drug-development
#16
Joseph A Goble
Enacted in December 2016, the 21st Century Cures Act is a pivotal piece of legislation that will influence the FDA drug and device approval process for the foreseeable future. Although this legislation received overwhelming support by members of Congress for much needed budgetary increases for the FDA and other national health organizations, there is much controversy over certain provisions that potentially diminish the robustness of the evidence base required for drug and medical device approvals. This article discusses the key provisions from "Title III - Development" under "Division A - 21st Century Cures" related to drug development and, specifically, explores those aspects that address patient-focused drug development, use of surrogate endpoints in clinical trials, modernization of trial design, and use of real-world evidence for decision making and health care economic information...
July 2018: Journal of Managed Care & Specialty Pharmacy
https://www.readbyqxmd.com/read/29952705/reframing-the-value-of-treatments-for-relapsed-refractory-multiple-myeloma
#17
Sikander Ailawadhi, Sumeet Panjabi, Marco Campioni, Istvan Majer, Andrzej Jakubowiak
Ailawadhi reports research support from Pharmacyclics and consulting relationships with Takeda, Amgen, and Celgene. Jakubowiak reports consulting and advisory board relationships with AbbVie, Amgen, BMS, Celgene, Karyopharm, SkylineDX, and Takeda. Panjabi, Campioni, and Majer are employees of and stockholders in Amgen.
July 2018: Journal of Managed Care & Specialty Pharmacy
https://www.readbyqxmd.com/read/29952704/treatment-patterns-among-patients-with-psoriatic-arthritis-treated-with-a-biologic-in-the-united-states-descriptive-analyses-from-an-administrative-claims-database
#18
Jessica A Walsh, Oluwakayode Adejoro, Benjamin Chastek, Jacqueline B Palmer, Peter Hur
BACKGROUND: In patients with psoriatic arthritis (PsA), limited data exist regarding patterns of biologic therapy use. OBJECTIVE: To examine treatment patterns and therapy modifications in U.S. patients with PsA receiving a tumor necrosis factor inhibitor (TNFi) or an anti-interleukin (IL)-12/23 inhibitor. METHODS: Adults with PsA who newly initiated a biologic therapy (index biologic) between January 1, 2013, and January 31, 2015, were included from the Optum Research Database...
July 2018: Journal of Managed Care & Specialty Pharmacy
https://www.readbyqxmd.com/read/29952703/the-effect-of-fda-drug-safety-communications-on-patterns-of-tiotropium-dispensing-a-u-s-health-plan-claims-database-study
#19
Jacqueline M Major, Esther H Zhou, Yulan Ding, Thomas Ly, Jie Li, Simone P Pinheiro, Sally Seymour
BACKGROUND: The FDA issued 2 main drug safety communications (DSCs) on the cardiovascular safety of tiotropium in March 2008 (warning of a potential increased stroke risk) and January 2010 (informing of an absence of a significant increased stroke risk or cardiovascular events based on findings from a large trial). OBJECTIVE: To describe the effect of the FDA DSCs on medication dispensing of tiotropium in a large U.S. claims database. METHODS: Initiation of tiotropium products among patients with chronic obstructive pulmonary disease (COPD) aged 40 years and older was determined monthly from 2006-2012 using medication dispensing from the IMS Lifelink Health Plan Claims Database...
July 2018: Journal of Managed Care & Specialty Pharmacy
https://www.readbyqxmd.com/read/29952702/the-authors-respond
#20
Josh J Carlson, Gregory F Guzauskas, Richard H Chapman, Patricia G Synnott, Shanshan Liu, Elizabeth T Russo, Steven D Pearson, Elizabeth D Brouwer, Daniel A Ollendorf
Funding for the Carlson et al. study was provided in part by the Institute for Clinical and Economic Review. Ollendorf, Synnott, Chapman, and Pearson disclosed grants from Blue Shield of California Foundation, California Health Care Foundation, Laura and John Arnold Foundation, Aetna, AHIP, Anthem, Blue Shield of California, CVS Caremark, Express Scripts, Harvard Pilgrim Health Care, OmedaRx, United Healthcare, Kaiser Permanente, Premera, AstraZeneca, Genentech, GlaxoSmithKline, Johnson & Johnson, Merck, National Pharmaceutical Council, Takeda, Pfizer, Novartis, Lilly, Spark Therapeutics, Sanofi, Prime Therapeutics, and Health Care Service Corporation...
July 2018: Journal of Managed Care & Specialty Pharmacy
journal
journal
49618
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"